FrancophonIA/ELRC3.0 huggingface dataset:
English: Cross resistance to delavirdine and efavirenz is expected after virologic failure with nevirapine.
Croatian: Nakon virološkog neuspjeha nevirapina, očekuje se ukrižena rezistencija i na delavirdin i efavirenz.
English: If a patient is already taking St. John‘s Wort check nevirapine and if possible viral levels and stop St. John‘s Wort.
Croatian: Ako bolesnik već uzima gospinu travu, valja provjeriti razine nevirapina i ako je moguće broj virusnih razina te prekinuti primjenu gospine trave.
English: Any patient experiencing severe rash or a rash accompanied by constitutional symptoms such as fever, blistering, oral lesions, conjunctivitis, facial oedema, muscle or joint aches, or general malaise should discontinue the medicinal product and immediately seek medical evaluation.
Croatian: Svaki bolesnik koji dobije težak osip ili osip popraćen općim simptomima kao što su vrućica, stvaranje mjehurića, oralne lezije, konjunktivitis, edem lica, bolovi u zglobovima i mišićima ili opća malaksalost mora prekinuti terapiju lijekom i odmah potražiti liječničku pomoć.
English: Stavudine AUC  0.96 (0.89-1.03) Stavudine Cmin ND Stavudine Cmax  0.94 (0.86-1.03)
Croatian: Stavudin AUC  0,96 (0,89-1,03) Stavudin Cmin NO Stavudin Cmax  0,94 (0,86-1,03)
English: PHARMACEUTICAL FORM AND CONTENTS 90 prolonged-release tablets
Croatian: OBLIK I SADRŽAJ 90 tableta s produljenim oslobađanjem
English: Hypersensitivity (anaphylactic reaction, angioedema and urticaria) have been reported.
Croatian: Prijavljeni su slučajevi preosjetljivosti (anafilaktička reakcija, angioedem i urtikariju).
English: If ASAT or ALAT increase to > 5 ULN during treatment, nevirapine should be immediately stopped.
Croatian: Ako se AST ili ALT povise na > 5 x GGN tijekom liječenja, terapija nevirapinom se mora odmah prekinuti.
English: However, patients should be advised that they may experience adverse reactions such as fatigue during treatment with Viramune.
Croatian: Međutim, bolesnike treba upozoriti da tijekom liječenja Viramuneom mogu dobiti nuspojave, kao što je umor.
English: Viramune prolonged-release n=505
Croatian: Viramune s produljenim oslobađanjem n=505
English: The following patients are at increased risk of developing liver problems: - women - infected with hepatitis B or C - abnormal liver function tests - treatment-naïve patients with higher CD4 cell counts at the start of Viramune therapy (women more than 250 cells/mm³, men more than 400 cells/mm³) - pre-treated patients with detectable HIV-1 plasma viral load and higher CD4 cell counts at the start of Viramune therapy (women more than 250 cells/mm³, men more than 400 cells/mm³)
Croatian: Slijedeće skupine bolesnika su pod povećanim rizikom razvoja problema s jetrom: - žene - osobe inficirane hepatitisom B ili C - osobe s poremećenim rezultatima testova jetrene funkcije - bolesnici prethodno neliječeni antiretrovirusnim lijekovima, s povišenim brojem CD4 stanica na početku terapije Viramuneom (žene s više od 250 stanica/mm
English: Telbivudine is not a substrate, inducer or inhibitor of the cytochrome P450 (CYP450) enzyme system.
Croatian: Telbivudin nije supstrat, induktor niti inhibitor enzimskog sustava citokroma P450 (CYP450).
English: The frequencies given below are based on crude incidence rates of adverse reactions observed in the Viramune immediate-release (lead-in phase, table 1) and Viramune prolonged-release (randomised-phase/maintenance phase, table 2) groups of clinical study 1100.1486 with 1,068 patients exposed to Viramune on a backbone of tenofovir/emtricitabine.
Croatian: Dolje navedene učestalosti temelje se na neobrađenim stopama incidencije nuspojava opaženih u skupinama na Viramuneu s trenutnim oslobađanjem (uvodno razdoblje, tablica 1) i Viramune s produljenim oslobađanjem (razdoblje randomizacije, razdoblje održavanja, tablica 2) iż kliničkog ispitivanja 1100.1486 s 1 068 bolesnika izloženih Viramuneu na osnovnu terapiju tenofovirom/emricitabinom.
English: Hypersensitivity reactions can also occur as rash with other side effects such as: - fever - blistering of your skin - mouth sores - inflammation of the eye - swelling of the face - general swelling - shortness of breath - muscle or joint pain - a reduction in the number of your white blood cells (granulocytopaenia) - general feelings of illness - severe problems with liver or kidneys (liver or kidney failure).
Croatian: Reakcije preosjetljivosti se također mogu pojaviti u obliku osipa uz druge nuspojave kao što su: - vrućica - mjehurići na koži - ranice u ustima - upala oka - oticanje lica - opće oticanje - nedostatak zraka - bol u mišićima ili zglobovima - smanjenje broja bijelih krvnih stanica (granulocitopenija) - opći osjećaj bolesti - teški problemi s jetrom ili bubrezima (zatajenje jetre ili bubrega).
English: Bottles contain 90 prolonged-release tablets.
Croatian: Bočice sadrže 90 tableta s produljenim oslobađanjem.
English: MARKETING AUTHORISATION HOLDER Boehringer Ingelheim International GmbH Binger Strasse 173
Croatian: NOSITELJ ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET Boehringer Ingelheim International GmbH Binger Strasse 173
English: Cartons containing 30 prolongedrelease tablets or 90 prolonged-release tablets.
Croatian: Kutije sadrže 30 tableta s produljenim oslobađanjem ili 90 tableta s produljenim oslobađanjem. ili
English: After the lead-in period the incidence of symptomatic hepatic events was 2.4 % in the Viramune immediate-release group and 1.6% in the Viramune prolonged-release group.
Croatian: Nakon uvodnog razdoblja, incidencija simptomatskih jetrenih događaja bila je 2,4 % u skupini na Viramuneu s trenutnim oslobađanjem te 1,6 % u skupini na Viramuneu s produljenim oslobađanjem.
English: After the lead-in period the incidence of symptomatic hepatic events was 2.4 % in the Viramune immediate-release group and 1.6 % in the Viramune prolonged-release group.
Croatian: Nakon uvodnog razdoblja, incidencija simptomatskih jetrenih događaja jetre bila je 2,4 % u skupini na Viramuneu s trenutnim oslobađanjem te 1,6 % u skupini na Viramuneu s produljenim oslobađanjem.
English: There is not enough evidence to substantiate that the absence of an increased risk for toxicity seen in pretreated women initiating nevirapine with an undetectable viral load (less than 50 copies/ml of HIV-1 in plasma) and CD4 cell counts above 250 cells/mm
Croatian: Nema dovoljno dokaza za zaključak da je odsutnost povećanog rizika toksičnosti viđen u prethodno liječenih žena na početku primjene nevirapina, s nedektabilnim virusnim opterećenjem (manje od 50 kopija HIV-1/ml u plazmi) i s brojem CD4 stanica iznad 250 stanica/mm
English: Coadministration of Viramune with elvitegravir in combination with cobicistat is not recommended (see section 4.4).
Croatian: Istodobna primjena Viramunea s elvitegravirom u kombinaciji s kobicistatom se ne preporučuje (vidjeti dio 4.4).
English: Polyvinyl chloride (PVC)/aluminium foil push-through blister units (blister card of 7 tablets).
Croatian: Blister od polivinilklorid (PVC)/aluminijske folije kroz kojeg se mogu protisnuti tablete (blister sa 7 tableta).
English: For patients with renal dysfunction requiring dialysis an additional 200 mg dose of nevirapine following each dialysis treatment is recommended.
Croatian: Za bolesnike s bubrežnom disfunkcijom koja zahtijeva dijalizu, preporučuje se dodatna doza od 200 mg nevirapina nakon svake dijalize.
English: Isolated cases of Stevens-Johnson syndrome or Stevens-Johnson/toxic epidermal necrolysis transition syndrome have been reported in this population.
Croatian: U ovoj skupini prijavljeni su izolirani slučajevi Stevens Johnsonovog sindroma ili sindroma prijelaza Stevens-Johnsonovog sindroma u toksičnu epidermalnu nekrolizu.
English: The dose is one 200 mg tablet per day for the first 14 days of treatment (“lead-in” period).
Croatian: Doza je jedna tableta od 200 mg na dan prvih 14 dana liječenja („uvodno“ razdoblje).
English: Polyvinyl chloride (PVC)/aluminium foil push-through blister units (blister card of 10 tablets).
Croatian: Blister od polivinilklorid (PVC)/aluminijske folije kroz kojeg se mogu protisnuti tablete (blister s 10 tableta).
English: Baseline HIV−1 viral load stratum (copies/ml)
Croatian: Početni stratum HIV−1 virusnog opterećenja (kopije/ml)
English: It is not recommended to coadminister atazanavir/ritonavir and Viramune (see section 4.4).
Croatian: Ne preporučuje se istodobna primjena atazanavir/ritonavira i Viramunea (vidjeti dio 4.4).
English: Entecavir is not a substrate, inducer or an inhibitor of cytochrome P450 (CYP450) enzymes.
Croatian: Entekavir nije supstrat, induktor ili inhibitor enzima citokroma P450 (CYP450).
English: Isolated cases of Stevens-Johnson syndrome or Stevens-Johnson/ toxic epidermal necrolysis transition syndrome have been reported in this population.
Croatian: U ovoj skupini prijavljeni su izolirani slučajevi Stevens Johnsnovog sindroma ili sindroma prijelaza Stevens-Johnsonovog sindroma u toksičnu epidermalnu nekrolizu.
English: Herbal preparations containing St. John‘s Wort and Viramune must not be co-administered (see section 4.3).
Croatian: Biljni pripravci koji sadrže gospinu travu i Viramune ne smiju se primjenjivati istodobno (vidjeti dio 4.3).
English: Fosamprenavir 1400 mg BID
Croatian: Fosamprenavir 1400 mg 2x/dan
English: Results of in vitro studies showed a weak antagonism of nevirapine by adefovir (see section 5.1), this has not been confirmed in clinical trials and reduced efficacy is not expected.
Croatian: Rezultati in vitro ispitivanja pokazali su slab antagonizam nevirapina s adefovirom (vidjeti dio 5.1), što nije povrđeno kliničkim ispitivanjima te se ne očekuje smanjena djelotvornost.
English: MARKETING AUTHORISATION NUMBER(S) EU/1/97/055/008 [30 prolonged-release]
Croatian: 12. BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/97/055/008 [30 s produljenim oslobađanjem]
English: Eighty-five patients (3 to < 18 years) received weight or body surface area dose-adjusted Viramune immediaterelease for a minimum of 18 weeks and then were switched to Viramune prolonged-release tablets (2 x 100 mg, 3 x 100 mg or 1 x 400 mg once daily) in combination with other antiretrovirals for 10 days.
Croatian: Viramune s trenutnim oslobađanjem najmanje tijekom 18 tjedana, a zatim su prebačeni na Viramune tablete s produljenim oslobađanjem (2 x 100 mg, 3 x 100 mg ili 1 x 400 mg jednom dnevno) u kombinaciji s drugim antiretrovirusnim lijekovima tijekom 10 dana.
English: If it has been more than 12 hours since the dose was due only take the next dose at the usual time.
Croatian: Ako je prošlo više od 12 sati od propuštanja doze, treba uzeti sljedeću dozu u uobičajeno vrijeme.
English: Viramune should be used within 6 months of opening the bottle.
Croatian: Viramune se treba upotrijebiti unutar 6 mjeseci nakon otvaranja boce.
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each ml of oral suspension contains 10 mg of nevirapine (as hemihydrate)
Croatian: NAVOĐENJE DJELATNE(IH) TVARI Jedan ml oralne suspenzije sadrži 10 mg nevirapina (u obliku hemihidrata)
English: The recommended dose of Viramune for patients initiating nevirapine therapy is one 200 mg immediate-release tablet daily for the first 14 days (this lead-in period should be used because it has been found to lessen the frequency of rash), followed by one 400 mg prolonged-release tablet once daily, in combination with at least two additional antiretroviral agents.
Croatian: Preporučena doza Viramunea za bolesnike koji počinju terapiju nevirapinom je jedna 200 mg tableta s trenutnim oslobađanjem dnevno tijekom prvih 14 dana (ovo uvodno razdoblje je potrebno s obzirom da primijećeno smanjuje učestalost osipa), a nakon toga jedna 400 mg tableta s produljenim oslobađanjem jedanput dnevno, u kombinaciji s najmanje dva dodatna antiretrovirusna lijeka.
English: 100-150 mg BID
Croatian: 100-150 mg 2x/dan
English: Rashes are usually mild to moderate, maculopapular erythematous cutaneous eruptions, with or without pruritus, located on the trunk, face and extremities.
Croatian: Osipi su obično blagi do umjereni makulopapularno eritematozno izbijanje kožnih promjena, s ili bez svrbeža, na trupu, licu i ekstremitetima.
English: A separate treatment initiation pack with 200 mg Viramune tablets is available for this lead-in period.
Croatian: Dostupno je posebno pakiranje Viramune 200 mg tablete za uvodno razdoblje.
English: Patients switching from Viramune immediate-release to Viramune prolonged-release TRANxITION (study 1100.1526) is a Phase 3 study to evaluate safety and antiviral activity in patients switching from Viramune immediate-release to Viramune prolonged-release.
Croatian: TRANxITION (ispitivanje 1100.1526) je isptivanje faze 3 koje ocjenjuje sigurnost i antivirusnu aktivnost kod bolesnika koji se prebacuju s Viramunea s trenutnim oslobađanjem na Viramune s produljenim oslobađanjem.
English: It is very important that you take only one Viramune tablet a day for the first 14 days (“lead-in” period).
Croatian: Vrlo je važno uzimati samo jednu Viramune tabletu na dan prvih 14 dana („uvodno“ razdoblje).
English: Patients experiencing rash during the 14-day lead-in period of 200 mg/day should not have their Viramune dose increased until the rash has resolved.
Croatian: Bolesnicima kod kojih se tijekom 14-dnevnog uvodnog razdoblja uz dozu od 200 mg/dan pojavi osip ne smiju povećavati dozu Viramunea dok se osip ne povuče.
English: However, patients should be advised that they may experience adverse reactions such as fatigue during treatment with nevirapine.
Croatian: Međutim, bolesnike treba upozoriti da tijekom liječenja nevirapinom mogu dobiti nuspojave, kao što je umor.
English: Viramune tablets contain less than 1 mmol sodium (23 mg) per tablet, that is to say essentially
Croatian: Viramune tablete sadrže manje od 1 mmol (23 mg) natrija po tableti, tj. zanemarive količine natrija.
English: Due to the metabolic pathway of telbivudine, no clinically relevant drug-drug interaction is expected.
Croatian: Zbog metaboličkog puta telbivudina ne očekuju se klinički značajne interakcije među lijekovima.
English: If you stop taking Viramune for more than 7 days your doctor will instruct you to start the 14 day 'lead-in' period with Viramune tablets (described above) once again, before returning to the once daily dose with Viramune prolonged-release tablets.
Croatian: Ako prekinete uzimanje Viramunea na dulje od 7 dana, liječnik će Vam preporučiti početak s 14dnevnim “uvodnim“ razdobljem uz Viramune tablete (prethodno opisano) još jedanput, prije vraćanja na jednokratnu dnevnu dozu Viramune tableta s produljenim oslobađanjem.
English: If you stop taking Viramune for more than 7 days your doctor will instruct you to start the 14 day 'lead-in' period with Viramune oral suspension (described above) once again, before returning to the once daily dose with Viramune prolonged-release tablets.
Croatian: Ako prekinete uzimanje Viramunea na dulje od 7 dana, liječnik će Vam preporučiti početak s 14dnevnim “uvodnim“ razdobljem s Viramune oralnom suspenzijom (prethodno opisano) još jedanput, prije vraćanja na dozu jednom dnevno s Viramune tabletama s produljenim oslobađanjem.
English: - if you have taken Viramune before and had to stop the treatment because you suffered from: - severe skin rash - skin rash with other symptoms for example: - fever - blistering - mouth sores - inflammation of the eye - swelling of the face - general swelling - shortness of breath
Croatian: - ako ste prije uzimali Viramune te ste morali prekinuti liječenje jer ste patili od: - teškog kožnog osipa - kožnog osipa s drugim simptomima, na primjer: - vrućica - pojava mjehurića - rane u ustima - upala oka - oticanje lica - opće oticanje
English: Darunavir/ritonavir 400/100 mg BID
Croatian: Darunavir/ritonavir 400/100 mg 2x/dan
English: ANTIFUNGALS Fluconazole
Croatian: ANTITROMBOTICI
English: Each prolonged-release tablet contains 400 mg nevirapine.
Croatian: Svaka tableta s produljenim oslobađanjem sadrži 400 mg nevirapina.
English: Each prolonged-release tablet contains 100 mg of lactose (as monohydrate).
Croatian: Jedna tableta s produljenim oslobađanjem sadrži 100 mg laktoze (u obliku hidrata).
English: If you stop taking Viramune for more than 7 days your doctor will instruct you to start the 14 day 'lead-in' period (described above) once again, before returning to the twice daily dose.
Croatian: Ako prekinete uzimanje Viramunea na dulje od 7 dana, liječnik će Vam preporučiti početak s 14dnevnim “uvodnim“ razdobljem (prethodno opisano) još jedanput, prije vraćanja na dozu dvaput dnevno.
English: Each prolonged-release tablet contains 400 mg of lactose (as monohydrate).
Croatian: Jedna tableta s produljenim oslobađanjem sadrži 400 mg laktoze (u obliku hidrata).
English: The dose is one 200 mg Viramune tablet per day for the first 14 days of treatment (“lead-in” period).
Croatian: Doza je jedna Viramune 200 mg tableta na dan prvih 14 dana liječenja (uvodno razdoblje).
English: As granulocytopenia, drug reaction with eosinophilia and systemic symptoms, anaphylactic reaction, jaundice, hepatitis fulminant (which may be fatal), urticaria, decreased blood phosphorus and increased blood pressure during the lead-in phase with Viramune immediate release were not seen in study 1100.1486 the frequency category was estimated from a statistical calculation based on the total number of patients exposed to nevirapine immediate-release in the lead-in phase of the randomised controlled clinical study 1100.1486 (n= 1,068).
Croatian: S obzirom da granulocitopenija, reakcija na lijek uz eozinofiliju i sistemske simptome, anfilaktička reakcija, žutica, fulminantni hepatitis (može biti fatalan), urtikarija, smanjene vrijednosti fosfora u krvi i povišeni krvni tlak tijekom uvodnog razdoblja Viramunea s trenutnim oslobađanjem nisu viđeni u ispitivanju 1100.1486, kategorija učestalosti je procijenjena iz statističkog izračuna ukupnog broja bolesnika izloženih nevirapinu s trenutnim oslobađanjem u uvodnom razdoblju randomiziranog kontroliranog kliničkog ispitivanja 1100.1486 (n= 1 068).
English: Viramune oral suspension contains less than 1 mmol sodium (23 mg) per dosage unit, that is to say essentially ‘sodium-free'.
Croatian: Viramune oralna suspenzija sadrži manje od 1 mmol (23 mg) natrija po doznoj jedinici, tj. zanemarive količine natrija.
English: In a single dose pharmacokinetic study of 200 mg Viramune immediate-release tablets in HIV-negative patients with mild and moderate hepatic impairment (Child-Pugh A, n=6; Child-Pugh B, n=4), a significant increase in the AUC of nevirapine was observed in one Child-Pugh B patient with ascites suggesting that patients with worsening hepatic function and ascites may be at risk of accumulating nevirapine in the systemic circulation.
Croatian: U farmakokinetičkim ispitivanjima Viramune 200 mg tableta s trenutnim oslobađanjem u jednokratnoj dozi u HIV-negativnih bolesnika s blagim i umjerenim oštećenjem jetre (Child-Pugh A, n=6; ChildPugh B, n=4), opažen je značajan porast AUC nevirapina u jednog Child-Pugh B bolesnika s ascitesom, što upućuje da bolesnici s pogoršanjem jetrene funkcije i ascitesom mogu biti pod rizikom akumulacije nevirapina u sistemskoj cirkulaciji.
English: Rhabdomyolysis has been observed in patients experiencing skin and/or liver reactions associated with nevirapine use.
Croatian: Opažena je rabdomioliza kod bolesnika s kožnim i/ili jetrenim reakcijama povezanim s primjenom nevirapina.
English: 3 for the groups receiving Viramune immediate-release and Viramune prolonged-release respectively.
Croatian: 3 za skupine na Viramuneu s produljenim oslobađanjem.
English: In a 200 mg nevirapine single dose pharmacokinetic study of HIV-negative patients with mild and moderate hepatic impairment (Child-Pugh A, n=6; Child-Pugh B, n=4), a significant increase in the AUC of nevirapine was observed in one Child-Pugh B patient with ascites suggesting that patients with worsening hepatic function and ascites may be at risk of accumulating nevirapine in the systemic circulation.
Croatian: U farmakokinetičkim ispitivanjima nevirapina od 200 mg u jednokratnoj dozi u HIV-negativnih bolesnika s blagim i umjerenim oštećenjem jetre (Child-Pugh A, n=6; Child-Pugh B, n=4), primijećen je značajan porast AUC nevirapina u jednog Child-Pugh B bolesnika s ascitesom, što upućuje da bolesnici s pogoršanjem jetrene funkcije i ascitesom mogu biti pod rizikom akumulacije nevirapina u sistemskoj cirkulaciji.
English: Viramune 200 mg tablets nevirapine
Croatian: Viramune 200 mg tablete nevirapin
English: Viramune administration above the recommended dose might increase the frequency and seriousness of skin reactions, such as Stevens-Johnson syndrome and toxic epidermal necrolysis.
Croatian: Primjena Viramunea u dozama iznad preporučenih može povećati učestalost i ozbiljnost kožnih reakcija, kao što su Stevens-Johnsonov sindrom i toksična epidermalna nekroliza.
English: Viramune oral suspension contains 150 mg sucrose per ml.
Croatian: Viramune oralna suspenzija sadrži 150 mg saharoze u 1 ml.
English: Nevirapine must not be administered to patients with pretreatment ASAT or ALAT > 5 ULN until baseline ASAT/ALAT are stabilised < 5 ULN (see section
Croatian: Nevirapin se ne smije primjenjivati na bolesnicima koji imaju AST ili ALT >5 x GGN prije početka liječenja sve dok se vrijednosti AST/ALT ne stabiliziraju na razini < 5 x GGN (vidjeti dio 4.3).
English: The recommended dose of Viramune is one 200 mg tablet daily for the first 14 days (this lead-in period should be used because it has been found to lessen the frequency of rash), followed by one 200 mg tablet twice daily, in combination with at least two additional antiretroviral agents.
Croatian: Preporučena doza lijeka Viramune je jedna tableta od 200 mg dnevno tijekom prvih 14 dana (ovo uvodno razdoblje je potrebno s obzirom da primijećeno smanjuje učestalost osipa), a nakon toga jedna tableta od 200 mg dvaput dnevno, u kombinaciji s najmanje dva dodatna antiretrovirusna lijeka.
English: The results suggest that supplementing nevirapine therapy for adults with an additional 200 mg immediate-release tablet following each dialysis treatment would help offset the effects of dialysis on nevirapine clearance.
Croatian: Rezultati ukazuju da bi nadopunjavanje terapije odraslih osoba s dodatnih 200 mg Viramunea nakon svake dijalize pomoglo uklanjanju učinka dijalize na klirens nevirapina.
English: Rifampicin 600 mg QD
Croatian: Rifampicin 600 mg 1x/ dan
English: If ASAT and ALAT return to baseline values and if the patient had no clinical signs or symptoms of hepatitis, rash, constitutional symptoms or other findings suggestive of organ dysfunction, it may be possible to reintroduce nevirapine, on a case by case basis, at the starting dose regimen of Viramune immediate-release once daily for 14 days followed by Viramune prolonged-release tablets once daily.
Croatian: Ako se AST i ALT vrate na početne vrijednosti te ako bolesnik nema kliničkih znakova ili simptoma hepatitisa, osipa, općih simptoma ili drugih nalaza koji ukazuju na disfunkciju organa, moguće je ponovo uvesti nevirapin na temelju analize svakog pojedinog slučaja, s početnom dozom Viramunea s trenutnim oslobađanjem jednom dnevno u trajanju od 14 dana, iza čega slijedi Viramune tablete s produljenim oslobađanjem jednom dnevno.
English: anaphylactic reaction, angioedema, urticaria), drug reaction with eosinophilia and systemic symptoms, anaphylactic reaction
Croatian: Poremećaji imunološkog sustava Manje često preosjetljivost (uključujući anafilaktičku reakciju, angioedem, urtikariju), reakcija na lijek uz eozinofiliju i sistemske simptome, anafilaktička reakcija
English: No clinically relevant drug-drug interaction is expected.
Croatian: Ne očekuju se klinički značajne interakcije među lijekovima.
English: In adult patients with renal dysfunction requiring dialysis an additional 200 mg dose of nevirapine immediate-release following each dialysis treatment is recommended.
Croatian: Odraslim bolesnicima s disfunkcijom bubrega kojima je potrebna dijaliza preporučuje se dodatna doza od 200 mg nevirapina s trenutnim oslobađanjem nakon svakog liječenja dijalizom.
English: Maraviroc 300 mg QD
Croatian: Maravirok 300 mg 1x/dan